These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. [Thrombocytopenia due to heparin therapy. Use of danaparoid (Orgaran), 13 monocentric cases under authorization of temporary prescription (ATU)]. Gindre L; de Maistre E; Perrin A; Lecompte T; Hoffman MA Therapie; 1997; 52(6):591-7. PubMed ID: 9734113 [TBL] [Abstract][Full Text] [Related]
9. Anticoagulative management of patients requiring left ventricular assist device implantation and suffering from heparin-induced thrombocytopenia type II. Christiansen S; Jahn UR; Meyer J; Scheld HH; Van Aken H; Kehrel BE; Hammel D Ann Thorac Surg; 2000 Mar; 69(3):774-7. PubMed ID: 10750760 [TBL] [Abstract][Full Text] [Related]
10. [Thrombosis of a cardiopulmonary bypass circuit despite recommended hypocoagulation with danaparoid during the acute phase of type II heparin-induced thrombocytopenia]. Salmi L; Elalamy I; Leroy-Matheron C; Houel R; Thébert D; Duvaldestin P Ann Fr Anesth Reanim; 2006; 25(11-12):1144-8. PubMed ID: 17174213 [TBL] [Abstract][Full Text] [Related]
11. Orgaran during rotational atherectomy in the setting of heparin-induced thrombocytopenia. Hale LP; Smith K; Braden GA; Owen J Cathet Cardiovasc Diagn; 1998 Nov; 45(3):318-22. PubMed ID: 9829897 [TBL] [Abstract][Full Text] [Related]
12. [Peri-operative anticoagulation with danaparoid for a patient with Budd-Chiari syndrome and heparin-induced thrombocytopenia]. Brémaud M; De Maistre E; Junke E; Guerci A; Lalot JM; Longrois D; Lecompte T; Meistelman C Ann Fr Anesth Reanim; 2004 Feb; 23(1):50-5. PubMed ID: 14980323 [TBL] [Abstract][Full Text] [Related]
13. [Extracorporeal circulation with danaparoid sodium for valve replacement in thrombocytopenia induced by type II heparin]. Salmi L; Leroy-Matheron C; LeBesnerais P; Rosanval O; Duvaldestin P; Gouault-Heilmann M Ann Fr Anesth Reanim; 2001 Nov; 20(9):799-802. PubMed ID: 11759322 [TBL] [Abstract][Full Text] [Related]
14. Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia. Wilde MI; Markham A Drugs; 1997 Dec; 54(6):903-24. PubMed ID: 9421696 [TBL] [Abstract][Full Text] [Related]
15. On the prophylactic and therapeutic use of danaparoid sodium (Orgaran) in patients with heparin-induced thrombocytopenia. Schenk JF; Pindur G; Stephan B; Mörsdorf S; Mertzlufft F; Kroll H; Wenzel E; Seyfert UT Clin Appl Thromb Hemost; 2003 Jan; 9(1):25-32. PubMed ID: 12643320 [TBL] [Abstract][Full Text] [Related]
16. Danaparoid for cardiopulmonary bypass in patients with previous heparin-induced thrombocytopenia. Gillis S; Merin G; Zahger D; Deeb M; Drenger B; Hyam E; Eldor A Br J Haematol; 1997 Sep; 98(3):657-9. PubMed ID: 9332322 [TBL] [Abstract][Full Text] [Related]
17. Drugs for the prevention and treatment of thrombosis in patients with heparin-induced thrombocytopenia. Lubenow N; Greinacher A Am J Cardiovasc Drugs; 2001; 1(6):429-43. PubMed ID: 14728002 [TBL] [Abstract][Full Text] [Related]
18. [Cardiac surgery in patients with heparin-induced thrombocytopenia (HIT II)]. Jović MD; Nezić DG; Calija BM; Nenadić DS; Knezević AM; Borzanović MD; Krivokapić BM; Petrović IM; Djukanović BP Acta Chir Iugosl; 2009; 56(1):47-52. PubMed ID: 19504989 [TBL] [Abstract][Full Text] [Related]
20. Heparin-induced thrombocytopenia in paediatric patients--a review of the literature and a new case treated with danaparoid sodium. Ranze O; Ranze P; Magnani HN; Greinacher A Eur J Pediatr; 1999 Dec; 158 Suppl 3():S130-3. PubMed ID: 10650852 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]